Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results

Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results

Abstract: Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib (ibr) revolutionized chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treatment, although treatment-related toxicities limit the use of some BTK inhibitors. Zanubrutinib, a potent next-generation BTK inhibitor, has...

Full description

Saved in:
Bibliographic Details
Main Authors: Mazyar Shadman, John M. Burke, Jennifer Cultrera, Habte A. Yimer, Syed F. Zafar, Jamal Misleh, Subramanya S. Rao, Charles M. Farber, Aileen Cohen, Hui Yao, Adam Idoine, Qi An, Ian W. Flinn, Jeff P. Sharman
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952925002733
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items